開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
歐盟委員會發言人:歐盟正在重新評估之前所宣佈的舉行歐盟/英國峯會的機會。
2026-06-22
歐盟委員會發言人:歐盟正在重新評估之前所宣佈的舉行歐盟/英國峯會的機會。
返回
其他消息
2026-06-22
On June 22, Qatari prime minister and foreign minister Mohammed said Qatar’s top priority is defusing regional tensions and restoring calm and stability. He urged all parties to resolve disputes diplomatically to prevent escalation, warning that any flare-up anywhere in the Middle East, including Lebanon, could affect US–Iran negotiations. Mohammed said some states were attempting to disrupt the US–Iran talks, but mediators including Qatar detect willingness from both sides to seek a settlement.
On June 22, Qatari prime minister and foreign minister Mohammed said Qatar’s top priority is defusing regional tensions and restoring calm and stability. He urged all parties to resolve disputes diplomatically to prevent escalation, warning that any flare-up anywhere in the Middle East, including Lebanon, could affect US–Iran negotiations. Mohammed said some states were attempting to disrupt the US–Iran talks, but mediators including Qatar detect willingness from both sides to seek a settlement.
2026-06-22
The National Medical Products Administration, via its priority review channel, has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang). Indication: adults with recurrent or metastatic nasopharyngeal carcinoma who progressed after at least two lines of systemic chemotherapy and prior PD‑1/PD‑L1 inhibitor therapy. The approval adds a new treatment option for this patient cohort.
The National Medical Products Administration, via its priority review channel, has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang). Indication: adults with recurrent or metastatic nasopharyngeal carcinoma who progressed after at least two lines of systemic chemotherapy and prior PD‑1/PD‑L1 inhibitor therapy. The approval adds a new treatment option for this patient cohort.
Chat with us
, powered by
LiveChat